227 related articles for article (PubMed ID: 16724286)
1. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.
Curtis JR; Westfall AO; Allison JJ; Freeman A; Saag KG
Osteoporos Int; 2006; 17(8):1268-74. PubMed ID: 16724286
[TBL] [Abstract][Full Text] [Related]
2. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
Martin KE; Yu J; Campbell HE; Abarca J; White TJ
J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
[TBL] [Abstract][Full Text] [Related]
4. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.
Downey TW; Foltz SH; Boccuzzi SJ; Omar MA; Kahler KH
South Med J; 2006 Jun; 99(6):570-5. PubMed ID: 16800411
[TBL] [Abstract][Full Text] [Related]
5. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
[TBL] [Abstract][Full Text] [Related]
6. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.
Cramer JA; Amonkar MM; Hebborn A; Altman R
Curr Med Res Opin; 2005 Sep; 21(9):1453-60. PubMed ID: 16197664
[TBL] [Abstract][Full Text] [Related]
7. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
Iwamoto J; Takeda T; Sato Y
Expert Opin Pharmacother; 2007 Nov; 8(16):2743-56. PubMed ID: 17956196
[TBL] [Abstract][Full Text] [Related]
8. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
[TBL] [Abstract][Full Text] [Related]
9. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
Stovall DW; Beard MK; Barbier S; Chen E; Rosenberg E; de Papp AE
J Womens Health (Larchmt); 2010 Mar; 19(3):491-7. PubMed ID: 20141367
[TBL] [Abstract][Full Text] [Related]
10. Gaps in treatment among users of osteoporosis medications: the dynamics of noncompliance.
Brookhart MA; Avorn J; Katz JN; Finkelstein JS; Arnold M; Polinski JM; Patrick AR; Mogun H; Solmon DH
Am J Med; 2007 Mar; 120(3):251-6. PubMed ID: 17349448
[TBL] [Abstract][Full Text] [Related]
11. Agreement and validity of pharmacy data versus self-report for use of osteoporosis medications among chronic glucocorticoid users.
Curtis JR; Westfall AO; Allison J; Freeman A; Kovac SH; Saag KG
Pharmacoepidemiol Drug Saf; 2006 Oct; 15(10):710-8. PubMed ID: 16498575
[TBL] [Abstract][Full Text] [Related]
12. Changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate.
Takada J; Iba K; Imoto K; Yamashita T
J Bone Miner Metab; 2007; 25(2):142-6. PubMed ID: 17323185
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
14. Adherence to osteoporosis medications amongst Singaporean patients.
Cheen MH; Kong MC; Zhang RF; Tee FM; Chandran M
Osteoporos Int; 2012 Mar; 23(3):1053-60. PubMed ID: 21503813
[TBL] [Abstract][Full Text] [Related]
15. Comparison of direct health care costs related to the pharmacological treatment of osteoporosis and to the management of osteoporotic fractures among compliant and noncompliant users of alendronate and risedronate: a population-based study.
Blouin J; Dragomir A; Fredette M; Ste-Marie LG; Fernandes JC; Perreault S
Osteoporos Int; 2009 Sep; 20(9):1571-81. PubMed ID: 19107385
[TBL] [Abstract][Full Text] [Related]
16. Risk of upper gastrointestinal tract events in risedronate users switched to alendronate.
Ralston SH; Kou TD; Wick-Urban B; Steinbuch M; Masud T
Calcif Tissue Int; 2010 Oct; 87(4):298-304. PubMed ID: 20803291
[TBL] [Abstract][Full Text] [Related]
17. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
18. Hip fractures in users of first- vs. second-generation bisphosphonates.
Mamdani M; Kopp A; Hawker G
Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
[TBL] [Abstract][Full Text] [Related]
19. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.
Kherani RB; Papaioannou A; Adachi JD
Drug Saf; 2002; 25(11):781-90. PubMed ID: 12222989
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates. A cornerstone of osteoporosis treatment.
Mayo Clin Womens Healthsource; 2007 May; 11(5):1-2. PubMed ID: 17476171
[No Abstract] [Full Text] [Related]
[Next] [New Search]
